Edgewise Therapeutics, Inc. (EWTX)
NMS – Real Time Price. Currency in USD
43.87
-0.44 (-0.99%)
Market open: Aug 12, 2026, 12:33 PM EDT
44.31
0.00 (0.00%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
Find any stock by ticker or company name

NMS – Real Time Price. Currency in USD
43.87
-0.44 (-0.99%)
Market open: Aug 12, 2026, 12:33 PM EDT
44.31
0.00 (0.00%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
Revenue breakdown data has not been calculated yet.
No Data
There are no news for this stock.
Company's cash reserves $72.3M significantly exceed its total debt $3.6M, ensuring strong financial flexibility
Total current assets $471.5M exceed Total current liabilities $29.0M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$42.5M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 16.24 | 6.05 | 10 | |
| Quick ratio | 16.24 | 5.63 | 10 | |
| Debt to Equity | 0.01 | 0.30 | 10 | |
| Debt to Assets | 0.01 | 1.04 | 10 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 8.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | -538K | -2M | -2M | -2M | -2M |
| Operating Income | -72M | -114M | -159M | -191M | -219M |
| Net Income | -68M | -100M | -134M | -168M | -197M |
| EBITDA | -71M | -113M | -157M | -189M | -217M |
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Gross margin % | N/A | -11.73 | 1.0 | |
| Operating margin % | N/A | -24.60 | 1.0 | |
| Net margin % | N/A | -172.20 | 1.0 | |
| EBITDA margin % | N/A | -201.27 | 1.0 | |
| Cash flow margin % | N/A | -156.39 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | -37.18 | 1.0 |
| Next quarter | N/A | -1.87 | 1.0 |
| Current year | N/A | -26.23 | 1.0 |
| Next year | N/A | 22.9 | 5.5 |
| Weighted average score | 2.1 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | -16.95 | -15.21 | 0.71 | 3.5 |
| Y/Y | 999 | -58.72 | -55.87 | -30.23 | 3.3 |
| 3y average | 999 | -35.67 | -9.51 | -37.12 | 3.3 |
| 5y average | 999 | -63 | -9.98 | -62.38 | 3.3 |
| Weighted average score | 3.4 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |